Dopamine transporter (DAT) activity is also believed to be critically involved in the dopaminergic dysfunction associated with ADHD and, therefore, should constitute a crucial molecular target for the treatment of this disease [13]. This evidence concerns the gene SLC6A3 and attention deficit-hyperactivity disorder.